United Kingdom

People: AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

6:47pm BST
Change (% chg)

$-0.46 (-2.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Wendell, Amy 

Ms. Amy McBride Wendell is an Lead Independent Director of the AxoGen, Inc. She has been a senior advisor for the healthcare investment banking practice of Perella Weinberg Partners (“PWP”) since January 2016. Her scope of responsibilities involves providing guidance and advice with respect to mergers and acquisitions and divestitures for clients, and assisting PWP in connection with firm-level transactions. Since 2015, Ms. Wendell has also been a senior advisor for McKinsey and Company’s (“McKinsey”) strategy and corporate finance practice and also serves as a member of McKinsey’s transactions advisory board to help define trends in mergers and acquisitions, as well as help shape McKinsey’s knowledge agenda. From 1986 until January 2015, Ms. Wendell held various roles of increasing responsibility at Covidien plc (“Covidien”) (including its predecessors, Tyco Healthcare and Kendall Healthcare Products), including in engineering, product management and business development. Most recently, from December 2006 until Covidien’s acquisition by Medtronic plc in January 2015, Ms. Wendell served as Covidien’s Senior Vice President of Strategy and Business Development, where she managed all business development, including acquisitions, equity investments, divestitures and licensing/distribution, and led Covidien’s strategy and portfolio management initiatives. Ms. Wendell is a member of the board of directors of Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products with a strong position in women’s health. She is also a director of Por Cristo, a non-profit charitable medical service organization involved in health care work for at-risk women and children in Latin America. Ms. Wendell holds a Bachelor of Science degree in mechanical engineering from Lawrence Institute of Technology (n/k/a Lawrence Technological University) and a Master of Science degree in biomedical engineering from the University of Illinois.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 105,249
Fiscal Year Total, USD 105,249

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --